Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) EPS (Weighted Average and Diluted) (2018 - 2025)

Neurogene (NGNE) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.98 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Weighted Average and Diluted) rose 18.33% year-over-year to -$0.98, compared with a TTM value of -$4.1 through Sep 2025, down 17.48%, and an annual FY2024 reading of -$4.28, changed N/A over the prior year.
  • EPS (Weighted Average and Diluted) was -$0.98 for Q3 2025 at Neurogene, up from -$1.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.98 in Q3 2025 and bottomed at -$1.2 in Q3 2024.